The clinical benefit of genome-wide cfDNA testing cannot be extrapolated from CVS data
- PMID: 31690836
- DOI: 10.1038/s41436-019-0689-5
The clinical benefit of genome-wide cfDNA testing cannot be extrapolated from CVS data
Comment in
-
Response to Sistermans et al.Genet Med. 2020 Mar;22(3):659-660. doi: 10.1038/s41436-019-0687-7. Epub 2019 Nov 4. Genet Med. 2020. PMID: 31680122 No abstract available.
Comment on
-
Outcomes in pregnancies with a confined placental mosaicism and implications for prenatal screening using cell-free DNA.Genet Med. 2020 Feb;22(2):309-316. doi: 10.1038/s41436-019-0630-y. Epub 2019 Aug 8. Genet Med. 2020. PMID: 31391534
References
-
- Grati FR, Ferreira J, Benn P, et al. Outcomes in pregnancies with a confined placental mosaicism and implications for prenatal screening using cell-free DNA. Genet Med. 2019 Aug 8; https://doi.org/10.1038/s41436-019-0630-y [Epub ahead of print]. - DOI
-
- Toutain J, Goutte-Gattat D, Horovitz J, Saura R. Confined placental mosaicism revisited: Impact on pregnancy characteristics and outcome. PLoS ONE. 2018;13:e0195905. - DOI
-
- Robinson WP, Barrett IJ, Bernard L, et al. Meiotic origin of trisomy in confined placental mosaicism is correlated with presence of fetal uniparental disomy, high levels of trisomy in trophoblast, and increased risk of fetal intrauterine growth restriction. Am J Hum Genet. 1997;60:917–927. - PubMed - PMC
-
- McCowan LM, Figueras F, Anderson NH. Evidence-based national guidelines for the management of suspected fetal growth restriction: comparison, consensus, and controversy. Am J Obstet Gynecol. 2018;218:S855–S868. - DOI
-
- Pertile MD, Halks-Miller M, Flowers N, et al. Rare autosomal trisomies, revealed by maternal plasma DNA sequencing, suggest increased risk of feto-placental disease. Sci Transl Med. 2017;9:eaan1240. - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
